Drugs / ABBV-CLS-7262
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06425003 | May → Jul 2024 | — | Calico Life Sciences LLC | Completed | No outcome recorded |
| Phase 1 | NCT06310876 | Mar → May 2024 | — | Calico Life Sciences LLC | Completed | No outcome recorded |
| Phase 1 | NCT06145607 | Dec 2023 → Jan 2024 | — | Calico Life Sciences LLC | Completed | No outcome recorded |
| Phase 1 | NCT05763459 | Mar → May 2023 | — | Calico Life Sciences LLC | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05740813 | Mar 2023 → Oct 2024 | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Completed | No outcome recorded |
| Phase 2/3 | NCT04297683 | Jun 2020 → Jul 2027 expected | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-CLS-7262 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06145607 ↗ |
| Route | Oral | “ABBV-CLS-7262 is administered orally once per day for 24 weeks.” NCT05740813 ↗ |